Chen Xiaolin, Huang Wei, Li Hongjuan, Huan Yan, Mai Guoying, Chen Luming, Huang Hongqiang, Xu Haoxiang
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Gland Surg. 2020 Dec;9(6):2162-2174. doi: 10.21037/gs-20-851.
Pituitary tumors are among the most common intracranial tumors. Surgical resection is the most effective treatment for patients with pituitary tumors. Microscopic transsphenoidal surgery has become the first-choice surgical approach to treating this malignancy, although it has certain limitations. Neuroendoscopy has also been widely used for pituitary tumor surgery in recent years. This study aimed to compare the efficacy and safety of these two surgical options for the treatment of pituitary tumors.
We conducted a literature search of the PubMed, Embase, Cochrane Controlled Center Register of Controlled Trials (CENTRAL), Web of Science database, Google Scholar, and Baidu Scholar. Relevant articles published up to September 25, 2020 were retrieved and then meta-analyzed using RevMan software 5.1.
A total of 29 case-control studies involving 7,774 patients were included in the meta-analysis. There was no significant difference in gross tumor removal (GTR) (RR =1.11, 95% CI: 0.97-1.26, P=0.12) or hormone excess secretion (HES) remission (RR =1.08, 95% CI: 0.97-1.21, P=0.16) between the two groups. Endoscopic transsphenoidal surgery was associated with a lower incidence of diabetes insipidus (DI) than was microscopic transsphenoidal surgery (RR =0.76, 95% CI: 0.60-0.97, P=0.03).
Endoscopic transsphenoidal surgery does not significantly improve GTR or HES remission, but it can reduce the incidence of DI without increasing the rates of other complications.
垂体瘤是最常见的颅内肿瘤之一。手术切除是垂体瘤患者最有效的治疗方法。显微经蝶窦手术已成为治疗这种恶性肿瘤的首选手术方式,尽管它有一定局限性。近年来神经内镜也已广泛用于垂体瘤手术。本研究旨在比较这两种手术方式治疗垂体瘤的疗效和安全性。
我们对PubMed、Embase、Cochrane对照试验中心注册库(CENTRAL)、科学网数据库、谷歌学术和百度学术进行了文献检索。检索截至2020年9月25日发表的相关文章,然后使用RevMan软件5.1进行荟萃分析。
荟萃分析共纳入29项病例对照研究,涉及7774例患者。两组间肿瘤全切除(GTR)(RR =1.11,95%CI:0.97-1.26,P=0.12)或激素分泌过多缓解(HES)情况(RR =1.08,95%CI:0.97-1.21,P=0.16)无显著差异。与显微经蝶窦手术相比,内镜经蝶窦手术的尿崩症(DI)发生率更低(RR =0.76,95%CI:0.60-0.97,P=0.03)。
内镜经蝶窦手术并不能显著提高肿瘤全切除率或激素分泌过多缓解率,但可降低尿崩症发生率,且不增加其他并发症发生率。